Novartis Opens $23B Texas Cancer Treatment Plant in 2028

Cancer patients in Texas and across the South will soon have faster access to a groundbreaking treatment that delivers targeted radiation directly to cancer cells anywhere in the body.

Novartis announced plans to build its first Texas manufacturing facility in Denton, a 46,000-square-foot site dedicated to producing radioligand therapy treatments. Construction begins this year, with full operations expected by 2028.

The facility marks a major milestone in the company's $23 billion U.S. investment and becomes the fifth radioligand therapy manufacturing site nationwide. Existing facilities operate in New Jersey, Indiana, California, and Florida, creating a coast-to-coast network designed to get lifesaving treatments to patients quickly.

Speed matters tremendously with this therapy. Each dose is custom-made for individual patients and remains effective for only a limited time, making proximity to treatment centers critical.

The company's manufacturing network maintains an impressive track record, delivering over 99% of doses on the scheduled treatment day. This reliability means patients can count on receiving their personalized cancer therapy exactly when needed.

Denton's new facility will create specialized jobs in bioengineering, advanced manufacturing, quality control, and operations. These positions will support both the local economy and the broader mission of expanding access to next-generation cancer care.

The Ripple Effect

Radioligand therapy represents a fundamental shift in how doctors can fight cancer. Unlike traditional treatments that affect the whole body, this approach combines a targeting molecule with radioactive material to find and destroy cancer cells with precision.

Novartis is currently investigating radioligand therapy across multiple cancer types, including prostate, breast, colon, lung, brain, and pancreatic cancers. The company operates one of the deepest research pipelines in the industry, exploring applications from late-stage disease to earlier treatment settings.

The Texas location strengthens the entire Southern region's access to advanced cancer care. Patients who previously might have needed to travel across the country for treatment will have options closer to home, reducing stress during an already challenging time.

Governor Greg Abbott highlighted Texas's growing role as a biotech hub, noting the facility will help strengthen critical supply chains while bringing good-paying jobs to the region. The investment signals confidence in Texas's workforce and infrastructure for supporting advanced medical manufacturing.

As research continues and radioligand therapy expands to treat more cancer types in earlier stages, facilities like the Denton site will become increasingly vital for meeting patient demand across America.